News

PPD has posted a net income of $37.37m, or $0.32 per diluted share, compared to $17.2m, or $0.14 per diluted share, for the same period in 2010. For

IQ Therapeutics said doses up to 7.5 mg/kg have been administered, as per protocol. IQNLF is a fully human antibody developed using IQ Therapeutics’ proprietary technology – Cloning

The patents contain ADHD-use claims for the entire family of P2D’s first-in-class dopamine transport inhibitors, including PD2005 and PD2007. Initial studies indicate that P2D’s lead compounds are as

Provectus Pharmaceuticals has already concluded patient recruitment and treatment of all subjects in its PV-10 Phase 1 clinical trial for liver cancer in January 2011. Preliminary analysis of

The goal of the collaboration is to develop a therapeutic approach for Parkinson’s disease that combines the strengths of Lilly’s biologic, a modified form of glial cell derived

In the submission, Columbia Laboratories has requested Priority Review to the FDA. The NDA submission includes data from two Phase III clinical trials evaluating the use of Prochieve

TXA127 is a pharmaceutical grade formulation of a naturally occurring peptide known to stimulate early hematopoietic precursor cells in the bone marrow. The company will compare the time

Currently, Velcade is approved for intravenous use only for the patients who are suffering from multiple myeloma and for patients with mantle cell lymphoma who have received at

The acquisition of Lexi-Comp will enable Wolters Kluwer Health to further strengthen its position in the clinical decision support and point-of-care information segments and to provide customers with